Sanofi
Sanofi reveals promising data for FDA-delayed diabetes drug
September 14, 2016Research and Development, Sales and Marketing FDA, Lantus, Sanofi, iglarlixi
Sanofi has announced new Phase III data for its IGlarLixi combination drug for the treatment of diabetes, showing it could …
New Sanofi/Alphabet partnership names CEO
September 12, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alphabet, Sanofi, Verily, appointment, google
As part of the news that French drugmaker Sanofi and Google parent Alphabet’s life sciences firm Verily are to join …
Sanofi and Google forge $500 million diabetes partnership
September 12, 2016Research and Development, Sales and Marketing Alphabet, Sanofi, Verily, diabetes, google
Sanofi is set to join forces with Alphabet’s life sciences firm Verily in a $500 million partnership to develop diabetes …
Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target
August 30, 2016Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III
Sanofi and Regeneron have announced that their Praluent injection generated positive Phase III results investigating patients with an inherited form …
FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due
August 22, 2016Research and Development, Sales and Marketing NDA, Sanofi, appraisal, diabetes, iglarlixi, type 2, type-2, zealand
There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a …
MSD joins Medivation race, says reports
August 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds
August 17, 2016Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent
A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …
Sanofi launches dengue immunisation program in Brazil
August 15, 2016Research and Development, Sales and Marketing Brazil, Sanofi, Sanofi Pasteur, Vaccine, dengue, immunisation, vaccines
Sanofi has announced that it has initiated the first dengue immunisation public program in the Americas, with 500,000 individuals set …
Top ten stories in the pharmaceutical industry this week
August 5, 2016Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten
It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
EMA accepts MMA for rheumatoid arthritis treatment Sarilumab
August 1, 2016Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab
Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …
Earnings drop at Sanofi as it looks for a quick Medivation resolution
July 29, 2016Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings
Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …
Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin
July 28, 2016Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand
Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …
Sanofi says to co-develop Zika vaccine with US government
July 6, 2016Research and Development, Sales and Marketing Sanofi, US government, Vaccine, Zika virus, drug development, research
French drugmaker Sanofi (Euronext: SAN) said it will co-develop a Zika vaccine candidate with the US government. No financial details …
Sanofi signs confidentiality agreement with Medivation for due diligence access for potential deal
July 6, 2016Research and Development, Sales and Marketing Financial, M&A, MA, Medivation, Sanofi, deal, offer
Sanofi (Euronext: SAN) confirmed it has entered a confidentiality agreement with cancer drugmaker Medivation (Nasdaq: MDVN) under which it will …
Sanofi, Regeneron say cholesterol drug Praluent approved in Japan
July 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt
Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
